Traditional Chinese medicine hepatitis B powder for eliminating duplication of hepatitis B virus (HBV) and method for manufacturing same

Abstract

The invention relates to a traditional Chinese medicine hepatitis B powder for eliminating the duplication of hepatitis B virus (HBV) and a method for manufacturing the same. The traditional Chinese medicine hepatitis B powder for eliminating the duplication of hepatitis B virus (HBV) consists of the following medicaments of 2.6 percent of Bupleurum, 6.5 percent of radix scutellariae, 6.5 percent of radix isatidis, 4.3 percent of polyphylla, 2.6 percent of subprostrate sophora, 6.5 percent of selfheal, 3.8 percent of trumpetweed, 8.5 percent of dandelion, 8.5 percent of Ophiorrhiza pumila, 5 percent of fruit of glossy privet, 3.8 percent of processed rhizoma pinelliae, 7.7 percent of raw Atractylis ovata, 5 percent of raw yam, 6.5 percent of radix codonopsitis, 6.5 percent of glossy ganoderma, 5 percent of Salvia miltiorrhiza, 4.2 percent of rhizoma imperatae and 6.5 percent of medlar. The manufacturing method comprises the steps of selecting the medicaments, cleaning and drying, grinding the medicaments into powder and filling 9g of the medicine powder in every bag according to the above mass percent. Tested by clinical trial, the powder has the functions of clearing away heat and toxic material, reducing enzyme and eliminating jaundice, restricting the duplication of hepatitis B virus , enhancing immunologic function of bodies, restoring damaged stem cell, and preventing cirrhosis and liver cancer, and the like.

Description

technical field [0001] The invention relates to a medicine and a manufacturing method thereof, in particular to a medicine for treating hepatitis B and a manufacturing method thereof. technical background [0002] Viral hepatitis B is a worldwide disease caused by the hepatitis B virus (HBV). The incidence rate is high in developing countries. According to statistics, there are more than 280 million asymptomatic hepatitis B virus carriers (HBsAg carriers) in the world, and my country accounts for about 93 million. Most of them are asymptomatic, and 1 / 3 of them have clinical manifestations of liver damage. At present, there are 30 million hepatitis B patients in our country. Hepatitis B is characterized by slow onset, and subclinical and chronic types are more common. Anicteric HBsAg persistently positive patients tend to become chronic. [0003] There are many medicines for treating hepatitis B in the prior art, but they still have limitations. my country's traditional ...

AI Technical Summary

Problems solved by technology

[0003] There are many drugs for the treatment of hepatitis B in the prior art, but there are still limitations